NextCure, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $28.8M
- Price
- $6.29
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.64%
- Volume
- 37.0K
About
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
Quick stats
Shares outstanding4.6M
Computed float2.5M
Float / shares55.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001661059
Websitehttps://www.nextcure.com
AI Summary
AI-generated1/32
majorbullishoffering
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
Avere Therapeutics raised an additional $500 million in a private placement, supplementing a prior $320 million raise to fully fund the combined company's operations into 2029.
The financing, supported by a syndicate of top-tier investors including Venrock and Blackstone, is expected to close immediately prior to the merger with NextCure.
The merger remains on track for the second half of 2026, resulting in a combined company focused on the oral IL-23 therapy AVR-001.
Red flags
- Significant dilution expected with 449,668,672 as-converted shares outstanding post-merger